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Abstract
Background: The disability-adjusted life years (DALYs) summarize the burden of years of life lost (YLL) due to
premature mortality and years lost due to disability (YLD). Our aim was to estimate the burden of ischemic heart
disease (IHD) and chronic obstructive pulmonary disease (COPD) in Finland in 2012, and to examine, how much the
YLD are affected by the use of different data sources.
Methods: The YLL were calculated using mortality data for the Finnish 25–74-year-old population in 2012. The YLD
were calculated using data from the FINRISK 2012 survey (3041 males, 3383 females aged 25–74 years) and then
directly adjusted to the corresponding population. Different administrative registers on 1) hospital inpatient
episodes and specialist outpatient visits, 2) entitlement to specially reimbursed medicines, and 3) purchases of
prescribed medicines were used for estimation of the YLD in addition to self-reported data. The DALYs were
calculated without age-weighting.
Results: The YLL for IHD were 37.5 for males and 9.1 for females per 1000 population among 25–74-year-old
people in Finland in 2012. The YLD for IHD varied markedly depending on which data sources were used. All data
sources combined, the YLD per 1000 were 5.3 for males and 2.5 for females resulting in estimated 42.8 and 11.6
DALYs per 1000 due to IHD among males and females, respectively. For COPD, the YLL were 4.7 for males and 2.0
for females per 1000. Also for COPD, the YLD varied markedly depending on data sources used. The YLD per 1000
based on all data sources combined were 2.0 for males and 1.6 for females. As a result, estimated 6.7 and 3.6 DALYs
per 1000 were due to COPD among males and females, respectively.
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Conclusions: Especially for COPD, all mild disease cases could probably not be identified from the included
registers. Thereby, including survey data improved the coverage of the data. The YLD of IHD and COPD varied
markedly between the data sources used in the calculations. However, as YLL constituted a major part of DALYs for
these diseases, the variation in YLD did not lead to substantial variation in DALYs.
Keywords: Disability-adjusted life year, Disease burden, Health examination survey, Self-report, Register data,
Ischemic heart disease, Chronic obstructive pulmonary disease
Background
Disability-adjusted life year (DALY) is a summary
measure, which combines the burden of both premature
mortality and morbidity. One unit of DALY corresponds
to one lost year of ‘healthy’ life [1]. For DALYs, years of
life lost (YLL) due to premature mortality and years lost
due to disability (YLD) are counted and summed up. In
the framework of the Global Burden of Disease (GBD)
Study, the methods for calculating DALYs have been
continuously developed [1–3].
The calculation of DALYs includes several possible
sources of error. In the case of the YLL, the calculations
are reasonably straight-forward, if reliable data on causes
of death are available, and uncertainty over YLL mainly
exists due to ill-defined deaths. For YLD, accurate data
on morbidity on population level may be less readily
available. In Finland, data from many high-quality
administrative population registers are available for
researchers and widely utilized in public health research
[4–7]. However, most health care registers with a long
history of systematic data collection, concentrate on
hospitalizations, and thereby may not cover persons with
a less severe condition or chronic disease diagnosed a
long time ago and treated in outpatient clinics or on
private sector. Data on the prevalence of health prob-
lems which do not need hospitalizations may be identi-
fied from other registers, such as entitlement to specially
reimbursed medicines or medicine purchases but using
these data has also several limitations.
Complementing register data with population-based
health examination survey (HES) data may help to fill in
possible gaps in registers with more representative
prevalence rates as a result. Burden of disease studies
are currently dependent on severity data estimating the
distribution of severity levels of each condition from
asymptomatic to severe state [3]. Therefore, it is crucial
that also the less severe cases would be identified to
achieve accurate YLD estimates.
Ischemic heart disease (IHD) was the leading cause of
YLL in 2017 globally and in the European Union,
whereas chronic obstructive pulmonary disease (COPD)
ranked as seventh globally and as fifth in the European
Union [8, 9]. In Finland, IHD mortality has decreased
markedly but was still the leading cause of deaths in
2017, and, more practically, the cause of one in five
deaths among men and one in six deaths among women
in 2017 [10, 11]. COPD, on the other hand, was ranked
as fifth among the top 10 causes of death in Finland in
2017 [11].
The challenges related to using register data for deter-
mining prevalences are somewhat different for IHD and
COPD. Regarding IHD, the Finnish special health care
registers cover persons with IHD fairly well as most
cases have specialist outpatient visits or hospital visits in
long-term follow-up. Furthermore, a special reimburse-
ment right of medicines exists for IHD. For persons
without this right, the IHD diagnosis cannot be reliably
deduced on the basis of medicines used by them as
many medicines such as antihypertensive and cholesterol
lowering medicines are used for many other purposes as
well. Nitrates are, in contrast, almost exclusively used for
IHD. However, nitrates are now mainly used among
patients with severe conditions and multimorbidities.
Those patients are very likely to have the reimbursement
right for IHD.
For COPD, many medicines are currently used for
both COPD and asthma, yet previously long-acting
muscarinic receptor antagonists (LAMAs) were used
mainly for COPD. On the other hand, mainly severe
COPD patients or patients treated primarily for other
diseases but who may have milder COPD as a secondary
diagnosis are treated in hospitals in Finland.
This study is a part of a research project ‘Projections
of the burden of disease and disability in Finland’ [12].
Two diseases, namely IHD and COPD were selected to
represent diseases, which both have a considerable pub-
lic health importance but different kind of issues related
to availability and coverage of health data. Our aim was
to estimate the burden of IHD and COPD in Finland in
2012, and to examine, how much the YLD and thereby
the DALYs are affected by the use of different register
data sources or population-based HES data.
Methods
Data sources
Abundant data sources were utilized. Several national
Finnish administrative register data sources were used in
YLL and YLD calculations, whereas self-reported data
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from a population-based HES were used to complement
register data sources in YLD calculations.
Health examination survey data
The sample used in this study comes from the National
FINRISK Study, which has been described in detail earl-
ier [13]. Shortly, the National FINRISK Study is series of
cross-sectional population-based risk factor monitoring
surveys, which were carried out at 5-year intervals be-
tween 1972 and 2012. In the present study, data from
the FINRISK 2012 survey were used. Data were com-
pleted by comprehensive register information linked to
the survey, which made it possible to compare informa-
tion received from different data sources.
In 2012, a stratified random sample of 10,000 persons
aged 25–74 years covering five regions in Finland was
drawn from the population register. The five regions repre-
sent different geographical areas in Finland, but do not
cover the whole Finnish population. The invitees received a
self-administered questionnaire together with an invitation
to a health examination visit. In this study, all those partici-
pants who filled in and returned the self-administered ques-
tionnaire, either by mail or during the health examination
visit, were included (3041 males and 3383 females with
respective participation rates 61 and 68%) (Table 1).
Self-reported information on IHD and COPD was
based on responses to the survey questionnaire. The
questions on IHD were: 1) Have you suffered or received
treatment for angina pectoris (diagnosed by a doctor)
during the past year, 2) Have you ever been diagnosed
by a doctor for myocardial infarction, 3) coronary bypass
surgery ever, or 4) coronary angioplasty ever. The ques-
tion on COPD was 1) Have you suffered or received
treatment for chronic obstructive pulmonary disease
(COPD) (diagnosed by a doctor) during the past year. A
positive response in any of these questions was consid-
ered as subject having IHD or COPD, respectively.
Register data
For YLL calculations, mortality data for the whole of
Finland in 2012 (January 1st to December 31st, 2012)
were obtained from the StatFin database of the Statistics
Finland, which is an open database [14]. For the current
study, the number of deaths with IHD or COPD as the
underlying cause of death among the Finnish population
was retrieved separately for males and females. The mor-
tality data are cause-specific only and do not include any
estimates of ill-defined deaths that would be redistribu-
ted to IHD and COPD. The International Classification
of Diseases, 10th revision (ICD-10) codes I20–I25 were
used for IHD and codes J41–J44 for COPD. These are
the same ICD-10 codes for IHD and COPD that were
applied in the GBD 2017 study [1, 2]. The mortality data
were available in 5-year age categories. Because the survey
data were limited to age group 25–74 years, data on IHD
and COPD mortality for the same age groups were used
in the calculations of YLL. However, mortality data for all
age groups, including those not analyzed by us, are pre-
sented for informational purposes in Additional file 1.
For YLD calculations, data from several registers were
linked with the FINRISK survey data using the unique
personal identification code (PIC) of the residents in
Finland. All register records that preceded the date of
each participant’s survey participation were retrieved. All
persons with a record attesting that the person had been
diagnosed with either IHD or COPD were classified as
prevalent disease cases irrespective of the severity level
of the disease. The data sources are illustrated in Fig. 1.
The two register sources used for estimating the YLD
of IHD were 1) the Care Register for Health Care (a con-
tinuation of the Hospital Discharge Registry) including
hospital inpatient episodes and specialist outpatient
visits, and 2) entitlement to specially reimbursed medi-
cines from the Registers of the Social Insurance Institu-
tion of Finland. For COPD, additionally information on
purchases of prescribed medicines by the Anatomical
Therapeutic Chemical (ATC) Classification System code
from the Registers of the Social Insurance Institution of
Finland was used.
The Care Register for Health Care covers the health
care records of inpatients episodes in all hospitals since
1969, inpatient episodes in municipal health centers
since 1994 and specialist outpatient visits since 1998 in
Finland. The Care Register for Health Care includes one
or several diagnosis codes associated with each episode
up to a maximum of six diagnosis codes. All persons
who had any register record with ICD-10 code related to
IHD or COPD were classified as having the condition.
Table 1 Data characteristics of respondents in FINRISK 2012
surveya
Males Females
Participation, n (response rate %) 3041 (61%) 3383 (68%)
Age, mean (SD) 51.8 (14.0) 50.4 (14.1)
Survey questionnaire responses
Effort angina (angina pectoris)b 4.6% 2.1%
Myocardial infarction ever 3.6% 0.9%
Coronary bypass surgery ever 2.2% 0.3%





aAll figures are unadjusted
bThe disease was included in a list of diseases under a question: Have you
suffered or received treatment for any of the following diseases (diagnosed by
a doctor) during the past year (last 12months)?
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The same ICD-10 codes were applied as in the case of
mortality data (I20–I25 for IHD and J41–J44 for COPD).
Information on the entitlement to specially reimbursed
medicines from the Registers of the Social Insurance Insti-
tution of Finland is available since 1964. For IHD, there is
a separate medicine reimbursement code. Persons with
entitlement to specially reimbursed medicines on the basis
of having IHD could be identified according to IHD’s
reimbursement code. The criterion for IHD reimburse-
ment status is that a patient has clinically approved chronic
angina pectoris responding to medication, a patient has
had a myocardial infarction or severe constriction of
coronary arteries which has been confirmed in angiography
or a patient has had invasive treatments such as bypass
surgery or angioplasty. In the current study, a person was
classified as having IHD if the entitlement had started
before the date of the participant’s survey visit. In the case
of COPD, the Finnish medical reimbursement system
covers medicines for severe or very severe COPD with a
criterion of forced expiratory volume per 1 sec (FEV1)
below 40% after bronchodilation or FEV1 below 50% and
either one exacerbation treated in hospital or at least two
per oral treatments with corticosteroid prescribed for
COPD exacerbation, corresponding closest to the inter-
national Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stages 3 and 4 [15]. In practice, using
register data on the entitlement to specially reimbursed
medicines to identify COPD cases is complicated by the
coding system, as COPD shares a common medicine reim-
bursement code with asthma. The ICD code for the disease
Fig. 1 Data sources for YLD. YLD, years lived with disability; IHD, ischemic heart disease; ICD, International Classification of Diseases; COPD,
chronic obstructive pulmonary disease; ATC, Anatomical Therapeutic Chemical
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for which the reimbursement was entitled has been
gradually added to the register in connection to the reim-
bursement code with moderate coverage since 2003.
Thereby, persons with these two records in the Registers of
the Social Insurance Institution of Finland, the common
reimbursement code for asthma and COPD and an ICD
code record indicating that the reimbursement was due to
COPD could be classified as having COPD. Again, the
same ICD-10 codes were applied for COPD as for other
registers (J41–J44), but as explained above, the entitlement
was possible only in the case of severe COPD.
Information on purchase of prescribed medicines by
ATC code from the Registers of the Social Insurance Insti-
tution of Finland was derived to complement register data
sources for COPD and is reported combined with data on
the entitlement to specially reimbursed medicines. The data
on medicine purchases are available since 1995, and this
register includes all medicines prescribed by a physician
and purchased by the patient. However, most pulmonary
medicines are not uniquely used for COPD and treatment
guidelines for COPD have changed during last 20 years,
and therefore, the medicine purchase data was not an opti-
mal data source. In this study, the selected ATC codes
included medicines which were mainly used for COPD
before 2012 and available in Finland. The ATC codes
included were R03AL03–R03AL06 (combined inhaled
long-acting B2-sympatomimetics and muscarinic receptor
antagonists medication), R03AL08–R03AL09 (combined in-
haled long-acting B2-sympatomimetics, long acting LAMA
and steroid medication), R03BB04–R03BB07 (long-acting
inhaled LAMA medications) and R03DX07 (rofrumilast).
YLL, YLD and DALY calculations
DALYs for IHD and COPD were calculated without age-
weighting or time discounting and YLD were estimated
using prevalence-based approach in concordance with
GBD 2016 analyses [1]. All calculations were performed
separately for men and women. Since the survey data
covered participants aged 25–74 years, all analyses were
limited to this age group.
Years of life lost due to premature mortality (YLL)
The YLL were calculated by multiplying the number of
deaths in a given age group with the standard expected
years of life lost (SEYLL) from the WHO Standard Life
Table for Years of Life Lost [1]. We used the SEYLL for
the midpoint of each 5-year age group in the YLL calcu-
lations. As an example, for the age group 25–29 years
the SEYLL of 27-year-olds (65.09 years) were used. The
YLL in all included age groups (25–74 years) were then
summed up separately for males and females. In addition
to the absolute numbers of YLL, the YLL per 1000
population were calculated using the 25–74-year-old
population in Finland in the end of year 2012 (1,707,636
males and 1,714,309 females).
Years lived with disability (YLD)
YLD were calculated using the FINRISK 2012 survey
data (described above) [13]. The prevalences were calcu-
lated separately for the included data sources (two or
three national administrative registers and self-reported
data from the FINRISK survey) and weighted using sur-
vey weights to represent the 25–74-year-old population
in the study areas in 2012 and to adjust for the survey
non-participation. The weighted prevalences were then
directly adjusted to the whole Finnish population aged
25–74 in 2012 using population statistics from the
Statistics of Finland, which resulted in the estimated
numbers of males and females with the conditions in
Finland [16]. The numbers of persons were then multi-
plied with the weighted disability weights (see below) to
calculate the absolute number of YLD in Finland in 2012.
The YLD per 1000 population were also calculated.
DALY calculation
For the final DALY figures, the YLL and YLD were
summed up. In addition to the absolute numbers of
DALYs, the DALYs per 1000 population were calculated.
Disability weights
We used disability weights from the WHO GBD 2017
study [1, 2]. As there are disability weights for different
severity levels of IHD and COPD, we calculated
weighted disability weights for the two conditions based
on published severity distributions [3]. We weighted the
four disability weights for the four severity levels
(asymptomatic, mild, moderate and severe) with the esti-
mated proportion of persons with the condition in ques-
tion belonging to that severity level group. We did not
stratify the conditions into sub-groups with and without
heart failure. The resulting weighted disability weights
were 0.073 for IHD and 0.127 for COPD.
Results
Ischemic heart disease
The results for YLL, YLD and DALYs for IHD are pre-
sented per 1000 population in Table 2. The results for
corresponding absolute figures and according to a more
thorough classification by register sources as well as
including different combinations of data sources are
presented in Additional file 2.
The YLL for IHD were 37.5 for males and 9.1 for
females per 1000 population among 25–74-year-old
people in Finland in 2012 (Table 2).
The HES data resulted in higher IHD prevalence than
all included registers together (6.2% vs. 4.9 and 2.4% vs.
2.2% for males and females, respectively), and combining
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register data and HES data elevated the prevalence even
further (to 7.3% for males and 3.4% for females) (Table
2). Thereby, the YLD varied markedly depending on
which data sources were used to estimate the prevalence.
All data sources combined, the YLD per 1000 population
were 5.3 for males and 2.5 for females.
The YLD constituted a minor part of total DALYs
compared to YLL. However, the contribution of YLD to
total DALYs varied considerably depending on which
data sources were used to calculate YLD (6.6–12.4% and
9.8–21.4% among males and females, respectively)
(Table 2, Fig. 2).
Using data from all three registers and from HES
resulted in estimated 42.8 DALYs per 1000 population
and 11.6 DALYs per 1000 population due to IHD among
males and females, respectively (Table 2). The DALYs
increased by about four and 10 % for males and females,
respectively, when data from all sources instead of data
from the Care Register for Health Care only were used.
The DALYs for IHD were about four-fold among males
compared to females.
The absolute number of DALYs due to IHD was 73,
017 for males and 19,916 for females (Additional file 2).
Chronic obstructive pulmonary disease
The results for YLL, YLD and DALYs for COPD are
presented per 1000 population in Table 3. The results
for corresponding absolute figures and according to a
more thorough classification by register sources as well
as including different combinations of data sources are
presented in Additional file 3.
The YLL for COPD were 4.7 for males and 2.0 for
females per 1000 population among 25–74-year-old
people in Finland in 2012 (Table 3).
The different register sources resulted in substantial
differences in the estimated COPD prevalence. HES data
resulted in quite similar prevalence estimates as all
included registers together (1.2% vs. 1.1 and 0.8% vs.
0.9% for males and females, respectively), but combining
both register data and HES data elevated the prevalence
estimates considerably (to 1.6% for males and to 1.3%
for females) (Table 3). The YLD per 1000 population
based on all data sources combined were 2.0 for males
and 1.6 for females.
The proportion of YLD of total DALYs varied consid-
erably depending on data sources selected to calculate
YLD (14.4–30.2% and 22.5–44.1% among males and
females, respectively) in accordance with the variation of
the observed prevalences by data source (Table 3,
Fig. 3).
Combining data from all sources resulted in estimated
6.7 and 3.6 DALYs per 1000 population due to COPD in
Finland in 2012 among men and women, respectively
(Table 3). The DALYs increased by about 17 and 38%
for males and females, respectively, when data from all
sources instead of data from the Care Register for Health
Care only were used. The DALYs for COPD were almost
two-fold among males compared to females.
The absolute number of DALYs due to COPD was 11,
472 for males and 6166 for females (Additional file 3).
Discussion
Using several instead of single register sources resulted
in higher prevalence estimates for IHD and even more
so for COPD. Moreover, using HES data in addition to
register data increased the prevalence rates and thereby
the YLD and DALY estimates, which we believed to im-
prove the accuracy of the final figures. More than 90,000
DALYs were caused by IHD and almost 18,000 by
Table 2 Prevalences and YLL, YLD and DALYs for IHD in Finland per 1000 population using administrative health register and self-












YLL per 1000 = 37.5
Prevalence (%) 4.8 3.6 4.9 6.2 7.3
YLD per 1000 3.5 2.7 3.6 4.5 5.3
DALYs per 1000 40.9 40.1 41.0 42.0 42.8
Females
YLL per 1000 = 9.1
Prevalence (%) 2.0 1.4 2.2 2.4 3.4
YLD per 1000 1.4 1.0 1.6 1.8 2.5
DALYs per 1000 10.6 10.1 10.7 10.9 11.6
YLL Years of life lost, YLD Years lived with disability, DALYs Disability-adjusted life years, IHD Ischemic heart disease, HES Health examination survey
aThe Care Register for Health Care includes hospital inpatient episodes since 1969 and specialist outpatient visits since 1998
bFrom the Registers of the Social Insurance Institution of Finland
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COPD in Finland in 2012. Per 1000 population, these
figures correspond to 43 DALYs for males and 12
DALYs for females for IHD and 7 DALYs for males and
4 DALYs for females for COPD. Premature mortality
(i.e. YLL) accounted for a major part of the DALYs for
IHD, whereas for COPD, also morbidity (i.e. YLD)
caused substantial burden.
The figures in this study are calculated based on ob-
served data on individual level from several separate data
sources, which included both register data and self-
reported data from a population-based HES. Yet, our
study has several limitations, especially with respect to
the study material. Only the age group 25–74 years was
included, as we have HES data only for this age group.
However, as can be observed from the Additional file 1,
the number of both IHD and COPD deaths increase
after 75 years of age. Thereby, the upper age limit of 75
excludes a significant number of IHD and COPD cases.
However, the SEYLL are small in the oldest age groups,
and estimating the final effect of exclusion of the over
75-year-old population is not simple. In a study from the
United States, the YLL, YLD and DALYs for myocardial
infarction and COPD were actually lower among over
80-year-olds than in the 10-year age groups between 50
and 79 years [17]. By contrast to the exclusion of the eld-
erly age groups, setting the lower age limit to 25 years
Fig. 2 Total YLD for IHD in Finland in 2012 and the proportion of YLD of DALYs1. YLD, years lived with disability; IHD, ischemic heart disease;
DALYs, disability-adjusted life years; HES, health examination survey. 1The percentages of YLD of DALYs are presented above each bar
Table 3 Prevalences and YLL, YLD and DALYs for COPD in Finland per 1000 population using administrative health register and self-
reported survey data from the FINRISK 2012 survey
The Care Register
for Health Carea









YLL per 1000 = 4.7
Prevalence (%) 0.8 0.6 1.1 1.2 1.6
YLD per 1000 1.0 0.8 1.3 1.5 2.0
DALYs per 1000 5.7 5.5 6.0 6.2 6.7
Females
YLL per 1000 = 2.0
Prevalence (%) 0.5 0.7 0.9 0.8 1.3
YLD per 1000 0.6 0.9 1.1 1.0 1.6
DALYs per 1000 2.6 2.9 3.1 3.0 3.6
YLL Years of life lost, YLD Years lived with disability, DALYs Disability-adjusted life years, COPD Chronic obstructive pulmonary disease, HES Health
examination survey
aThe Care Register for Health Care includes hospital inpatient episodes since 1969 and specialist outpatient visits since 1998
bData on the 1) entitlement to specially reimbursed medicines and 2) purchase of prescribed COPD medicines from the Registers of the Social Insurance
Institution of Finland combined
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instead of birth was likely to have a negligible effect on
the results in this study. In future studies, the results of
this study might be used for extrapolation to include
older age groups to the DALY estimations or even same
age groups as in our study but where data sources are
less abundant.
We used the GBD Results Tool [18] and compared
our results to those for the same age groups in Finland
in 2012. Our YLD estimates were higher for IHD and
lower for COPD than those used in the GBD study. We
were able to combine individual level health data from
different sources, whereas the Institute for Health Met-
rics and Evaluation (IHME) uses aggregated data and re-
sults published in scientific literature to estimate burden
of disease metrics. This may have allowed us to obtain
more precise estimates, since we did not have to rely on
so many modelling assumptions.
Our survey sample only included survey participants,
i.e. those who at least filled in and returned the survey
questionnaire. However, non-participants are likely to be
younger, less well educated, non-married, smokers, and
have a less favourable health status and higher mortality
in general [19–23]. In our study, we used survey weights
to account for the effect of non-participation bias with
respect to age, sex and area. However, it is possible that
non-participation depended on the outcomes of interest,
thus the prevalences might be underestimated.
Also the register data contains possible flaws and
sources of error. Regarding the calculation of YLL, we
relied on mortality data from Statistics Finland. Ill-
defined deaths in mortality data might have caused
inaccuracy in the number of IHD or COPD deaths and
thereby led to inaccuracy in our YLL estimates. This
inaccuracy is likely to be very small, as the Finnish na-
tional legislation and practices in cause of death investiga-
tion aim at a very accurate cause of death determination
and the percentage of “garbage coded” deaths in Finland
has been estimated to be only 5 % [24, 25].
For YLD, one of the limitations is that our data does
not cover visits to primary health care units. Unfortu-
nately, register data on primary care are available with a
good coverage in Finland only since 2013 while we used
register records until each person’s survey visit during
January–May 2012. In future studies, data from primary
health care units would, however, evidently improve the
coverage of register data especially for COPD, as persons
with milder or asymptomatic COPD do not necessarily
visit special health care units.
By contrast, the Care Register for Health Care (a con-
tinuation of the Hospital Discharge Registry) has a long
history of systematic data collection, and has been widely
utilized for health monitoring and research purposes in
Finland [6, 7]. For IHD events, the diagnoses of fatal and
non-fatal IHD events in the Hospital Discharge Register
and Causes of Death register were estimated to be
reasonably valid already more than 15 years ago [26].
More recently, the validity of heart failure diagnoses in
the Hospital Discharge Register, ie. the Care Register for
Health Care, was examined, with a conclusion that for
this condition, the register data were reliable [27].
Several issues complicate the use of register data in
identifying COPD cases. Firstly, in case that a COPD
patient meets the diagnostic criteria for asthma, the
disease may in many cases have been registered as
asthma for medical reimbursement. Asthma as a diagno-
sis is also less stigmatized for the patient. Secondly,
Fig. 3 Total YLD for COPD in Finland in 2012 and the proportion of YLD of DALYs1. YLD, years lived with disability; COPD, chronic obstructive pulmonary
disease; DALYs, disability-adjusted life years; HES, health examination survey. 1The percentages of YLD of DALYs are presented above each bar
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COPD and asthma share the same code for the entitle-
ment to specially reimbursed medicines from the Regis-
ters of the Social Insurance Institution of Finland, and it
was not possible to differentiate between the two
diseases in older data of this register where no ICD code
was recorded in connection to the entitlement code.
Thus, we could only utilize the more recent records
from this register. In addition, the entitlement to spe-
cially reimbursed medicines for COPD is only possible
for severe COPD. Therefore, we complemented COPD
data with the register on purchases of prescribed medi-
cines. Some subjects who may not have an entitlement
to specially reimbursed medicines but use medicines for
the condition may have been identified based on their
medicine purchases.
Undoubtedly, our data sources do not cover all diagnosed
COPD cases, let alone persons who have not been diag-
nosed and are unaware of their COPD status. To achieve
reliable data on COPD, spirometry and bronchodilator test
should be included in the survey protocol as has been done
in some surveys. In Finland, the Health 2000 and Health
2011 surveys included spirometry [28, 29]. A post-
bronchodilator test finding suggesting airway obstruction
(forced expiratory volume per 1 sec (FEV1) / forced vital
capacity (FVC) < 70%) [15] was observed in 11% of males
and 6% of females in 2000 and 13 and 9% in 2011. The
Health 2000 and Health 2011 surveys included participants
who were at least 30 years old with no upper age limit. In
both surveys, the prevalence of suggestive airway obstruc-
tion increased markedly with age, although it should be
acknowledged that the cut-off (FEV1/FVC < 70%) leads to
overestimates among the elderly [30]. For working age
population only (30–64 years) in 2000, the prevalence was
substantially lower than when the older participants were
included: 6% for males and 3% for females [28].
Unfortunately, it was not possible to adequately esti-
mate the actual severity level of IHD and COPD from
the registers or HES data to apply the different disability
weights for each severity level of these diseases. There-
fore, we applied the severity level distributions estimated
for the GBD study for IHD and COPD [3]. It should be
borne in mind, however, that the severity distributions
have been estimated on the basis of two studies from the
United States and one from Australia, and may not
ideally reflect the severity distributions in Finland [31].
In Scotland, national weighted disability weights have
been calculated for 21 cancer types based on local sever-
ity distributions and compared to disability weights
weighted using GBD 2016 global severity distributions
[32]. The severity distributions used in GBD 2016 study
differed markedly from the Scottish national severity
distributions with higher disability weight estimates in a
large majority of the selected cancer types. Furthermore,
assuming that all asymptomatic or milder COPD cases
could not be identified from our data sources, the sever-
ity distributions that were used might not reflect the
severity distributions of our data. In comparison to using
only register data, including self-reported data probably
helped to identify less severe cases as well.
Assuming that we were not able to identify all asymp-
tomatic or milder COPD cases, we performed a sensitiv-
ity analysis and upscaled the prevalences according to
the proportions of estimated severity distributions [3].
The calculation was based on an assumption that only
severe or moderate cases were identified from our data
sources. These upscaled prevalence rates were about
three-fold compared to those that were calculated apply-
ing the severity distributions directly to our actual data
(Additional file 4), and led to considerably higher
proportions of YLD of DALYs (for males 55.3% and for
females 69.3% compared to 30.2 and 44.1%, respectively,
including all data sources). In Scotland, it has been esti-
mated that 31% of disease burden due to COPD in 2015
was from morbidity [33], which is more similar with our
data without upscaling the prevalence rates.
For the two conditions examined in this study but
even more so for IHD, YLL, which rely on mortality
statistics, compose a major part of DALY. Thereby, the
variation in morbidity estimates (i.e. YLD) depending on
included data sources only led to moderate differences
in DALYs. This can also be illustrated by quantifying
how many additional persons suffering from IHD/COPD
in the whole Finnish population in 2012 would have led
to a 1 % increase in DALYs. This was about 10,000 and
2700 IHD cases and 900 and 490 COPD cases for men
and women, respectively.
There was considerable variation in the prevalence
rates and thereby the YLD estimates of IHD and COPD
when the results were reported separately for each indi-
vidual data source. As discussed above, all disease cases
may not be identified from the registers. Self-report, on
the other hand, may include overestimates, e.g. due to
possible misinterpretation of symptoms, such as assum-
ing dyspnea caused by other reasons to be heart disease
related. Combining information from several data
sources was, however, likely to improve the final DALY
estimates. Overall, the effect of variation in YLD esti-
mates on DALYs would probably be larger in the case of
diseases, which cause more morbidity in relation to pre-
mature mortality than IHD and COPD.
Conclusions
The different combinations of data sources markedly
affected the YLD of IHD and COPD. However, as
YLL constitute a major part of DALYs for these dis-
eases, the variation in YLD did not lead to substantial
variation in DALYs.
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Additional file 1. Deaths in ischemic heart disease (IHD) (ICD-10 codes
I20–I25) and COPD (chronic obstructive pulmonary disease) (ICD-10
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underlying cause of death and the population of Finland (December
31st, 2012) and by 5-year age groups. Description of data: Deaths in is-
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Additional file 2. Prevalences and YLL, YLD and DALYs for IHD in Finland
using administrative health register and self-reported survey data from the
FINRISK 2012 survey for all data sources separately and for different combi-
nations of data sources (3041 males, 3383 females). Description of data: YLL,
YLD and DALYs for IHD in absolute figures and per 1000 population by data
sources and including different combinations of data sources
Additional file 3. Prevalences and YLL, YLD and DALYs for COPD in
Finland using administrative health register and self-reported survey data
from the FINRISK 2012 survey for all data sources separately and for different
combinations of data sources (3041 males, 3383 females). Description of
data: YLL, YLD and DALYs for COPD in absolute figures and per 1000 popu-
lation by data sources and including different combinations of data sources
Additional file 4. Sensitivity analysis with upscaled prevalences and YLL,
YLD and DALYs for COPD in Finland per 1000 population using
administrative health register and self-reported survey data from the FIN-
RISK 2012 survey. Description of data: Sensitivity analysis with upscaled
prevalances for COPD
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